GOGeoVax Labs, Inc. GOVX · NASDAQ
$0.24 -7.56% (-$0.02)
- Market cap
- $2.51M
- Enterprise value
- -$306.7K
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -985.2%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 3.69
- Free float
- 100.0%
About the company
GeoVax Labs (GOVX) is a biotechnology company focused on the development of vaccines for the prevention and treatment of infectious diseases, such as HIV/AIDS, Ebola, Zika virus, and others. Using its patented technological approach, GeoVax develops vaccines aimed at providing effective protection against dangerous pathogens. The company also focuses on vaccine development for emerging threats in public health, including COVID-19. GeoVax Labs (GOVX) shares could be suitable for investors seeking opportunities in the biotechnology sector with a focus on vaccine research and development.
Sector
Healthcare
Industry
Biotechnology
CEO
David Alan Dodd
Employees
19
Headquarters
Smyrna
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number